Determination of Quinine Clearance in Chronic Renal Failure During Haemodialysis

Christophe N’cho Amin, Philippe André Sawa Kpaibé, Nicaise François Bony, Gildas Komenan Gbassi, Michèle Aké, Apollinaire Gnionsahé, Eugène Atindehou

1. Introduction

Chronic renal failure is a fairly common cause of hospitalization in internal medicine where his prognosis is terrible [1]. The common treatment is the dialysis. Hemodialysis is a method that used to achieve the extracorporeal removal of waste products such as creatinine, urea and free water from the blood when the kidneys are in a state of renal failure [2]. However, this treatment may reduce the effectiveness of certain drugs. It is necessary to study the dialysance of quinine, a drug used in first intention for the treatment of severe malaria due to the fragility of uremic patients and the presence of malaria in endemic areas. This study has been conducted at the hemodialysis center of SAMU (Service d’Aide Médicale d’Urgence) in Abidjan Cocody. Twenty one (21) subjects with chronic renal failure aged of 24 to 50 years were enrolled. Two groups of subjects were formed. Each patient of the first group (9 subjects) received per person one tablet of 500 mg of quinine base (single dose) before the hemodialysis started. The second group (12 subjects) received in perfusion 5% glucose solution (250 mL) containing 10 mg.kg⁻¹ of quinine base during 4 hours. The perfusion system and the hemodialysis system were conducted simultaneously. The concentrations of quinine in the tablet, the perfusion solution and the human blood were determined by a validated high performance liquid chromatography method. Quinine content in tablet and perfusion solution was in agreement with the manufacturer's specifications. The clearance of quinine was 23.67 mL.min⁻¹. It appeared of this study that quinine fraction extracted did not require dose adjustment.

Keywords: HPLC, Antimalarial, Quinine, Hemodialysis, Chronic Renal Failure
studied in subjects with chronic renal insufficiency during the dialysis session.

2. Material and Methods

The patients of the study are from the hemodialysis center of SAMU (Service d’Aide Médicale d’Urgence) in Abidjan Cocody. Analyses were conducted in the department of chemistry (Faculty of Pharmacy, University Félix Houphouët-Boigny). The protocol was approved by the hospital local ethics committee. Patients with chronic renal failure treated by regular haemodialysis participated in the protocol after providing informed consent.

2.1. Chemicals

All chemicals and solvents were of analytical grade from different suppliers. Quinine was from Sigma Aldrich (Saint Quentin Fallavier, France). Methanol, hydrochloric acid were from Sigma-Aldrich (Steinheim, Germany), acetonitrile HPLC grade from Panreac (Istanbul, Turkey), ammonium acetate GPR Rectapur from Prolabo (Paris, France), tetrahydrofuran Normapur from VWR Chemicals (Leicestershire, England). Quinimax® (Sanofi winthrop), commercial tablet and injectable formulations, were purchased from a pharmacy in Côte d’Ivoire.

2.2. Patients and Quinine Administration

Patients with chronic renal failure enrolled were 24 to 50 years old, sex male, hemoglobin upper to 8 g.dL\(^{-1}\) and serum protein upper than 65 g.L\(^{-1}\). Twenty one (21) subjects with chronic renal failure were enrolled. Two groups (1 and 2) of subjects were formed. Nine (9) subjects for group 1 received per os one tablet of 500 mg of quinine (single dose) before the hemodialysis started. The second group (12 patients) received in perfusion 5% glucose solution (250 mL) containing 10 mg.kg\(^{-1}\) of quinine base during 4 hours while the dialysis time was 5 hours. The perfusion system and the hemodialysis system was conducted simultaneously.

2.3. Blood Samples

Heparinized blood samples for determination of serum concentrations of quinine, urea and creatinine were obtained from artery and venous lines at 0, 30, 60, 120, 240 and 300 min when the patient is connected to hemodialysis system. Samples were centrifuged and plasma was stored at -70°C until analyzed.

2.4. Determination of Quinine

The concentrations of quinine in Quinimax® tablet, Quinimax® injectable solution for perfusion and in the human blood serum were determined by a high performance liquid chromatography (Shimadzu) method.

Standard solution and test solution

A standard solution containing 4.8 µg.mL\(^{-1}\) of quinine is prepared in a volumetric flask by agitation of an accurately weighed amount of quinine in methanol/hydrochloric acid 0.1equiv.L\(^{-1}\) (v/v).

Test solutions for tablet formulation corresponding to theoretical quinine concentration (4.8 µg.mL\(^{-1}\)) are prepared from an accurate amount of powdered tablet following the same procedure. After centrifugation of the extract at 5000 rpm for 5 min, the supernatant was injected in the chromatographic system.

Test solutions for injectable formulation corresponding to theoretical quinine concentration (4.8 µg.mL\(^{-1}\)) are prepared by dilution in the same working solution.

For blood serum sample treatment, a liquid/liquid extraction was applied to a whole blood sample using acetonitrile for the deproteinization. Centrifugation was set at 5,000 rpm for 15 min.

Apparatus and operating conditions

A Shimadzu HPLC equipment was used. A Supercosil column LC 25-cm x 4.6-mm, RP18 reverse-phase column was eluted with an acetonitrile/ammonium acetate buffer/ tetrahydrofuran: 15:60:25 (v/v/v), pH 3; at a flow rate of 1.0 mL.min\(^{-1}\). A fluorescence detector was set at 350 nm for excitation wavelength and 425 nm for emission wavelength.

2.5. Other Biochemical Assays

Urea and creatinine were determined respectively by an enzymatic (urease) method and by the Jaffe reaction.

2.6. Calculate of the Clearance

Substance clearance was determined by the formula \(C_l=Q_B\times(C_{A_{\text{Artery}}}-C_{V_{\text{Vein}}})/C_{A_{\text{Artery}}},\) where \(C_l = \text{clearance}; Q_B = \text{hemodialysis flow rate}, C_{A_{\text{Artery}}} \text{substance concentration in arterial blood and } C_{V_{\text{Vein}}} \text{substance concentration in venous blood.}

3. Results and Discussion

3.1. Preliminary Studies

The method used in this study derived from Sharma et al.’s method [7] due to its simplicity. Their mobile phase was consisted of acetonitrile/sodium acetate buffer 5 mmol.L\(^{-1}\) (23.77, v/v), pH 3. Sodium acetate buffer was replaced with ammonium acetate buffer because alkaloids are better separated in the presence of ammonium salt [8]. Quinine asymmetry peak obtained was corrected by adding tetrahydrofuran, an organic modifier [9]. The final mobile phase consisted of acetonitrile/ammonium acetate buffer/ tetrahydrofuran (15:60:25, v/v/v), pH 3.

3.2. Validation Method of Quinine Determination

Linearity of the calibration line over the range 0.02-20 µg.mL\(^{-1}\) \((r^2=0.999),\) recovery (in the range 94–102%), repeatability (RSD < 5%, \(n = 6\)) and LOD (2.10\(^{-7}\) µg.mL\(^{-1}\)) are summarized in the Table 1.

3.3. Determination of Quinine in Quinimax® Commercial Formulations

Quinine drug is frequently used to treat severe malaria in...
endemic regions. To prevent fake medicine, commercial quinine was analyzed before using by patients with chronic renal failure in the present study. Quinine content in tablet and injectable solution was in agreement with the manufacturer's specifications (Table 2).

### Table 1. Validation method of quinine determination in commercial formulation and in blood sample.

<table>
<thead>
<tr>
<th>Method</th>
<th>Pharmaceutical formulation</th>
<th>Blood serum sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linearity</td>
<td>y = 1451.7 x + 78.0, r^2 = 0.9999</td>
<td></td>
</tr>
<tr>
<td>Repeatability (n=6) of various standard solutions (0.35, 1, 2.4, 4.8 and 10 µg.mL(^{-1}))</td>
<td>1.36–1.71%</td>
<td></td>
</tr>
<tr>
<td>Repeatability of an extract (n=6)</td>
<td>1.3%</td>
<td>3.8%</td>
</tr>
<tr>
<td>Repeatability of the analytical procedure (n=6)</td>
<td>1.3%</td>
<td>4.9%</td>
</tr>
<tr>
<td>Recovery</td>
<td>99%</td>
<td>97.1%</td>
</tr>
<tr>
<td>Limit of quantification (LOQ, µg.mL(^{-1}))</td>
<td>2.10×10^-6</td>
<td></td>
</tr>
<tr>
<td>Limit of detection (LOD, µg.mL(^{-1}))</td>
<td>2.10×10^-7</td>
<td></td>
</tr>
</tbody>
</table>

### Table 2. HPLC determinations of quinine in commercial formulations.

<table>
<thead>
<tr>
<th>Form</th>
<th>Commercial formulation</th>
<th>Quinine (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Injectable solution</td>
<td>Quinimax 125(^{®}) containing 120 mg of quinine</td>
<td>120.99±4.03</td>
</tr>
<tr>
<td></td>
<td>Quinimax 250(^{®}) containing 240 mg of quinine</td>
<td>239.39±4.53</td>
</tr>
<tr>
<td></td>
<td>Quinimax 500(^{®}) containing 480 mg of quinine</td>
<td>490.62±8.03</td>
</tr>
<tr>
<td>Tablet</td>
<td>Quinimax 500(^{®}) containing 480 mg of quinine</td>
<td>494.55±9.37</td>
</tr>
</tbody>
</table>

### 3.4. Determination of Quinine, Urea and Creatinine During Dialysis

Quinine concentrations determined in artery blood and in venous blood after oral and intravenous administration of quinine were presented in figure 1. The concentrations of quinine in the artery blood and venous blood are not different after oral administration of quinine in all blood sampling. It is the same after intravenous administration of quinine at the end of quinine perfusion. Concentrations of urea and creatinine were shown in figure 2. These substances decrease during hemodialysis. Differences of ureaemia and creatininemia are respectively significant between artery blood and venous blood.

### 3.5. Calcul of Clearance

Quinine clearance after oral administration in the group 1 was 26.94±11.63 mL.min\(^{-1}\). The clearance after IV administration in the group 2 was 21.22±13.97 mL.min\(^{-1}\). The comparison of these quinine clearance is not significant (t=0.242 < t\(_{0.05\,(2.080)}\)). There were no significant changes in plasma quinine concentrations in patients with chronic renal failure during hemodialysis. Similar results were obtained in acute renal failure [10]. Non dialyzable quinine is also shown in two patients with severe malaria and renal failure requiring dialysis [7]. The clearance of quinine was evaluated to 23.67 mL.min\(^{-1}\). There is a low quinine fraction extracted compared to urea and creatinine. It represented respectively 14.97% and 18.70% of the clearance of urea (159.73±24.29) mL.min\(^{-1}\) and creatinine (124.96 ±22.44) mL.min\(^{-1}\).

### 4. Conclusion

Quinine content in tablet and injectable solution used for studying the clearance of quinine in hemodialysis was in agreement with the manufacturer's specifications. Similar quinine clearances in hemodialysis were noted after oral and IV administration. Quinine clearance during hemodialysis was 23.67 mL.min\(^{-1}\). The low quinine fraction extracted by an artificial kidney does not require a dose adjustment of this antimalarial treatment during hemodialysis.

![Figure 1. Concentration (C) of quinine during dialysis.](image)
Acknowledgment

The laboratory is grateful to Patrick Balley for his technical contribution.

References


